J
Jean-Jacques Grob
Researcher at Aix-Marseille University
Publications - 369
Citations - 58038
Jean-Jacques Grob is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 71, co-authored 310 publications receiving 45788 citations. Previous affiliations of Jean-Jacques Grob include University of Sydney.
Papers
More filters
Journal ArticleDOI
Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Beloo Mirakhur,Mary E. Guckert,R. Suzanne Swann,Patricia Haney,Anne-Marie Martin,Danielle Ouellet,Kelly M. Grotzinger,Vicki L. Goodman,Paul B. Chapman +16 more
TL;DR: Dabrafenib demonstrated a significant improvement in PFS and ORR over DTIC with an acceptable safety profile and benefits in P FS and RR were observed in all subgroups evaluated.
Journal ArticleDOI
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.
Claus Garbe,Teresa Amaral,Ketty Peris,Axel Hauschild,Petr Arenberger,Nicole Basset-Seguin,Lars Bastholt,Veronique Bataille,Véronique Del Marmol,Brigitte Dréno,Maria Concetta Fargnoli,A.M. Forsea,Jean-Jacques Grob,Christoph Höller,Roland Kaufmann,Nicole W.J. Kelleners-Smeets,Aimilios Lallas,Céleste Lebbé,Bodhan Lytvynenko,Josep Malvehy,David Moreno-Ramírez,P. Nathan,Giovanni Pellacani,Philippe Saiag,Alexander J. Stratigos,Alexander C.J. van Akkooi,Ricardo da Costa Barbedo Vieira,Iris Zalaudek,Paul Lorigan +28 more
TL;DR: In this article , the authors proposed a stage-based follow-up scheme to detect relapses and secondary primary melanomas as early as possible, according to the experience of the guideline group, but further studies may be considered.
Journal ArticleDOI
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006
Jacob Schachter,Antoni Ribas,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Teresa M. Petrella,Omid Hamid,Honghong Zhou,Scot Ebbinghaus,Nageatte Ibrahim,Caroline Robert +19 more
TL;DR: Pembro (anti–PD-1) provided superior OS and PFS and a lower incidence of grade 3-5 treatment-related AEs compared with ipi (anti-CT...
Journal ArticleDOI
Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Caroline Gaudy-Marqueste,A.-S. Dussouil,Romain Carron,L. Troin,N. Malissen,Anderson Loundou,Sandrine Monestier,Stéphanie Mallet,Marie Aleth Richard,J. Regis,Jean-Jacques Grob +10 more
TL;DR: In real-life MM pts with BMs, a strategy aiming at controlling BM with GK together with TT and/or TT seems to achieve unprecedented survival rates.
Journal ArticleDOI
How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life
TL;DR: This work sought to determine which regimen improves or better maintains QoL in CIU: desloratadine daily or PRN; and second‐generation H1‐antihistamines daily or when symptoms return.